Durvalumab After Sequential Chemoradiotherapy in Stage III Unresectable NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Thoracic Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial
J Thorac Oncol 2022 Aug 09;[EPub Ahead of Print], MC Garassino, J Mazieres, M Reck, C Chouaid, H Bischoff, N Reinmuth, L Cove-Smith, T Mansy, D Cortinovis, MR Migliorino, A Delmonte, JG Sánchez, LE Chara Velarde, R Bernabe, L Paz-Ares, ID Perez, N Trunova, K Foroutanpour, C Faivre-FinnFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.